Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance-Reference-Cited by-同舟云学术

Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

Published:2012-01 Issue:1 Volume:3 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Shi Hubing,Moriceau Gatien,Kong Xiangju,Lee Mi-Kyung,Lee Hane,Koya Richard C.,Ng Charles,Chodon Thinle,Scolyer Richard A.,Dahlman Kimberly B.,Sosman Jeffrey A.,Kefford Richard F.,Long Georgina V.,Nelson Stanley F.,Ribas Antoni,Lo Roger S.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms1727.pdf

Reference20 articles.

1. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).

2. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).

3. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

4. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).

5. Kefford, R. et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. 28 (Suppl) abstr. 8503 (2010).

Cited by 555 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Reversal of Drug Resistance in Cancer;Targets;2024-09-13

2. The Fanconi anemia pathway induces chromothripsis and ecDNA-driven cancer drug resistance;Cell;2024-08

3. Cross-Domain Feature Disentanglement for Interpretable Modeling of Tumor Microenvironment Impact on Drug Response;IEEE Journal of Biomedical and Health Informatics;2024-07

4. Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma;Cell Reports;2024-04

5. Background and clinical significance of biomarker-based patient enrichment in non-small-cell lung cancer drug development;Scientific Reports;2024-03-26